Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
合伙人律师
Pirozzolo, Jack W.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

False Claims Act Risk on the RadarTuesday, October 6, 2026
活动
U.S. Department of Justice Announces Major Justice Manual Revisions on Sub-Regulatory Guidance and Dismissals of FCA Qui TamsSeptember 21, 2026
Original Source
U.S. Department of Justice Announces Major Justice Manual Revisions on Sub-Regulatory Guidance and Dismissals of False Claims Act Qui TamsSeptember 21, 2026
Healthcare Update
DOJ Announces Largest Settlement Yet in Drive to Use the FCA to Target Alleged Employment DiscriminationSeptember 16, 2026
Original Source
Eleventh Circuit Rejects Appointments Clause Challenge to Qui Tam MechanismSeptember 2, 2026
Original Source
New York Ethics Opinion Warns Lawyers on Qui Tam DeceptionSeptember 2, 2026
Law360